DPP-4 inhibitors and lipids: systematic review and meta-analysis (Q34116689)

31 July 2017

0 references

DPP-4 inhibitors and lipids: systematic review and meta-analysis (English)

1 reference

31 July 2017

0 references

0 references

1 reference

Matteo Monami

1

1 reference

31 July 2017

Caterina Lamanna

series ordinal

2

1 reference

31 July 2017

Carla Maria Desideri

series ordinal

3

1 reference

31 July 2017

Edoardo Mannucci

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

22 December 2011

1 reference

31 July 2017

1 reference

31 July 2017

29

1 reference

31 July 2017

14-25

1 reference

31 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0088-z

31 July 2017

0 references

cites work

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0088-Z

10.1007/S12325-011-0088-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference